Citadel Advisors
KRSA

Citadel Advisors’s Korsana Biosciences, Inc. Common Stock KRSA Stock Holding History

Citadel Advisors’s Portfolio KRSA Stock Details KRSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-14
Closed -$868 – 14459
2023
Q1 		$868 Sell
14
-3
-18% -$38 ﹤0.01% 14406
2022
Q4 		$1.57K Buy
+17
New +$201 ﹤0.01% 14450
2022
Q1 		– Sell
-256
Closed -$62K – 13734
2021
Q4 		$62K Sell
256
-127
-33% -$6K ﹤0.01% 13119
2021
Q3 		$165K Sell
383
-340
-47% -$22.3K ﹤0.01% 12239
2021
Q2 		$395K Buy
+723
New +$45.3K ﹤0.01% 10594

Other funds holding KRSA

KCM
Kalehua Capital Management Dallas, Texas $174M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RC
Rangeley Capital New Canaan, Connecticut $109M AUM 97.13% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citadel Advisors's KRSA Position: Q2 2026 in Review

Citadel Advisors increased its Korsana Biosciences, Inc. Common Stock (KRSA) stake by 227% in Q2 2026, buying an estimated $19.3K and bringing the position to 8,542 shares worth $203K. The position accounts for ﹤0.01% of the portfolio, ranked #12043.

Citadel Advisors first reported a position in KRSA in Q2 2019 and has held it in 9 quarters since. The position peaked at $3.42M in Q2 2019. 21 funds tracked by Wall St. Rank hold KRSA as of Q2 2026.

  • Citadel Advisors held 8,542 shares of Korsana Biosciences, Inc. Common Stock worth $203K as of Q2 2026.
  • Citadel Advisors bought 5,933 Korsana Biosciences, Inc. Common Stock shares in Q2 2026, an estimated $19.3K.
  • Korsana Biosciences, Inc. Common Stock made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #12043 holding.
  • Citadel Advisors first reported a position in Korsana Biosciences, Inc. Common Stock in Q2 2019 and has held it in 9 quarters since.
  • Citadel Advisors's Korsana Biosciences, Inc. Common Stock position peaked at $3.42M in Q2 2019.
  • 21 funds tracked by Wall St. Rank held Korsana Biosciences, Inc. Common Stock as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.